Sun Pharma gets US nod for Nicardipine Hydrochloride Injections (HCI) for hypertension

Mumbai: Sun Pharmaceutical Industries Limited, based in India, has received final approval from the United States Food and Drug Administration (FDA) for the company’s application for Nicardipine Hydrochloride Injections (HCI), which is a short-term treatment for hypertension.

The Nicardipine Hydrochloride Injections, available in strength of 25 mg/10 ml, has an annual sale of about $170 million in the United States.

These injections are used for the short-term treatment of hypertension – or, higher-than-normal blood pressure – when oral therapy is either not feasible or not desirable.

Sun Pharmaceutical Industries Limited was founded in 1983, and listed since 1994.

The company makes as well as markets a large number of pharmaceutical formulations in India, the United States and many other countries across the world as branded generic drugs and generic drugs.

According to a statement from Sun Pharmaceutical Industries Limited, in India, the company is a leader in therapy areas of psychiatry, cardiology, neurology, gastroenterology, orthopedics and diabetology.

The company claims that it has “strong skills” in the spheres of product development, process chemistry, and manufacturing of complex API, and dosage forms.

More information about Sun Pharmaceutical Industries Limited can be had from its website www.sunpharma.com

Hypertension, or high blood pressure, is a chronic medical condition in which the blood pressure rises above normal. It is also referred to, in shortened forms, as HT, HTN, or HPN.

The word ‘hypertension’ normally refers to systemic, arterial hypertension.

Hypertension is usually classified as essential (primary) hypertension, or secondary hypertension.

For essential hypertension, as rule, no medical cause can be found to explain the elevated blood pressure. This is the common form of hypertension, and around 90%-95% of hypertension is essential hypertension.

Secondary hypertension is raised blood pressure which is a result of – that is, secondary to – another condition like kidney disease or tumours.

Continuing hypertension has been found to be one of the risk factors in causing strokes, heart attacks, heart failure, and arterial aneurysm. Also, it is a leading cause of chronic renal failure.